NEPHROCARE HEALTH SERV L Fair Value
NEPHROPLUS · Healthcare Services · Current price ₹635.7
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹107 | 9% ROE fading to 12% over ~3 yrs, on ₹111 book |
| Relative P/E | ₹496 | EPS × 64.7 peer-median P/E |
| Graham floor | ₹138 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is NEPHROCARE HEALTH SERV L undervalued?
DocStoX estimates the fair value of NEPHROCARE HEALTH SERV L at ₹221 per share, versus the current market price of ₹636. That puts the stock about -65.2% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹107), Relative P/E (₹496), Graham floor (₹138). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹107 (bear) to ₹221 (base) to ₹496 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on NEPHROCARE HEALTH SERV L
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.